Format

Send to

Choose Destination
Int Arch Allergy Immunol. 2012;159(2):179-82. doi: 10.1159/000336391. Epub 2012 Jun 1.

The safety of peanut oral immunotherapy in peanut-allergic subjects in a single-center trial.

Author information

1
Division of Immunology and Allergy, Stanford University, Stanford, CA, USA.

Abstract

BACKGROUND:

Peanut allergy is the leading cause of food-related anaphylaxis, and accidental exposures are common. Oral immunotherapy (OIT) has been posited as a potential treatment.

METHODS:

Patients aged 3-65 years with peanut-specific IgE ≥7 kU/l and/or a positive skin prick test with a history of an allergic reaction to peanut were recruited to undergo an OIT protocol. All adverse reactions were recorded by research staff or patients in real time.

RESULTS:

Twenty-four patients received 6,662 doses. Symptoms were mostly mild (84%), and only 3 severe gastrointestinal reactions required the administration of epinephrine. Abdominal pain was the most common reaction, followed by oropharyngeal and lip pruritus. Respiratory symptoms were rare.

CONCLUSIONS:

In this trial of OIT in adults and children, most reactions were mild.

PMID:
22678151
PMCID:
PMC3505766
DOI:
10.1159/000336391
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
Loading ...
Support Center